109 results about "Laminin" patented technology

The invention relates to the field of biological medicine and cosmetics, in particular to laminin RL-20 and application of the laminin RL-20 in cosmetics.

The invention discloses a composition with sensitive skin repairing and anti-aging functions as well as an emulsion and application of the composition, and belongs to the technical field of cosmetics. The composition specifically comprises a pseudoalteromonas fermentation product extract, collagen, palmitoyl tripeptide-5, acetylchitosamine, sodium hyaluronate, silanetriol, caffeine and acetyl hexapeptide-8, and can promote the generation of laminin-5 and integrin beta1, promote the vitality of keratinocytes and fibroblasts, inhibit the growth of the keratinocytes and the fibroblasts, inhibit the growth of the keratinocytes and the fibroblasts, inhibit the growth of the keratinocytes and the fibroblasts, and promote the growth of the keratinocytes and the fibroblasts. The generation of inflammatory factors (IL-6) is inhibited; the generation of collagen IV and collagen VII is promoted; the invention further provides an emulsion prepared from the composition, and the optimal formula of the emulsion is obtained through optimization. The active composition disclosed by the invention has a wide application prospect in the field of cosmetics, and particularly has important significance in sensitive skin repair and anti-aging directions.

The invention discloses a model for predicting the progression hepatic fibrosis risk of a WD long-term maintenance treatment patient and a design method thereof, and relates to the technical field of medical information, the prediction model comprises the following steps: an input module receives patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER), and the input module receives the patient parameter indexes composed of sex (SEX), platelet (PLT), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), laminin (LN) and copper cyanin (CER); the processing module obtains single scores corresponding to the seven independent risk factors, the single scores are added to obtain a total score, the prediction probability corresponding to the total score is the risk of the progression-stage hepatic fibrosis of the WD long-term maintenance treatment patient, and the prediction risk probability is output through the output module. The column diagram prediction model established by the invention has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of progression-stage hepatic fibrosis of WD long-term maintenance treatment patients.

The invention discloses recombinant laminin with anti-aging and repairing effects and a preparation method of the recombinant laminin, relates to the technical field of recombinant proteins, and aims to solve the technical problems that existing laminin is relatively low in yield and limited in application. According to the recombinant laminin with the anti-aging and repairing effects, the sequence of the recombinant laminin is shown as SEQ ID No.3, the total number is 363aa, and the predicted molecular weight is 40.4 kD. Compared with the prior art, the recombinant laminin is synthesized by embedding a laminin gene sequence into a pichia pastoris genome for heterologous expression. A cytological detection method for evaluating the efficacy of a skin care product is applied, and a research result shows that the recombinant laminin can remarkably promote cell adhesion and migration activity and can stimulate cells to generate collagen, so that the anti-aging and repairing functions of the recombinant laminin are shown.

The present invention relates to modified recombinant agrin proteins or fragments thereof and recombinant chimeric laminin-nidogen proteins or fragments thereof, nucleic acid sequences encoding these proteins, vectors containing these nucleic acid sequences, compositions comprising these proteins, and the use of these proteins in the prevention and / or treatment of congenital muscular dystrophies, in particular (laminin-α2) LAMA2-associated muscular dystrophy.

Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located on top of and within the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high levels of laminin-5, a cell adhesion bio-active factor shown to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

The invention relates to a hydrogel material containing laminin, the hydrogel material comprises a hydrogel body and an effective amount of laminin subunit arranged in the hydrogel body, and the laminin subunit is cross-linked with the hydrogel body. The laminin subunit can be added into the hydrogel, so that the polarity of the dental papilla cell of the miniature pig and the differentiation level of the dentin-forming cell are remarkably improved, the differentiation of the dentin-forming cell is directionally regulated and controlled, the differentiation level of the dentin-forming cell is effectively improved, the operation is simple, and the effect is remarkable. In addition, laminin subunits are added into the collagen-based hydrogel, so that the rigidity of the collagen hydrogel is improved, and the arrangement and mechanical strength of collagen fibers in the hydrogel are improved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of MIM2 and derivatives thereof in preparation of products for treating tissue fibrosis. It is found that the compound MIM2 can effectively inhibit expression and synthesis of various cancers (extracellular matrix proteins such as collagen and laminin in cells). In-vitro experiments show that after MIM2 treatment, collagen and laminin expression of the cancer cells, skin fibroblasts, hepatic stellate cells and embryonic lung cells is remarkably reduced. Animal experiments further prove that the MIM2 can effectively inhibit collagen deposition in tumor tissues of tumor-bearing mice, can slow down the fibrosis process of liver fibrosis and pulmonary fibrosis mouse models, and can reduce the level of plasma hyaluronic acid at the same time. The results show that the MIM2 has the effects of inhibiting extracellular matrix deposition and delaying tissue fibrosis, and is expected to be developed into small molecular drugs for treating cancer-related fibrosis and other fibrosis diseases.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.

The invention discloses a biomarker for monitoring the curative effect of a PD-1 antibody of a PD-L1Positive gastric cancer patient, and relates to the technical field of biomedical detection, and the biomarker is laminin gamma 2. According to the invention, the laminin gamma2 is used as a novel biomarker for monitoring the curative effect of the PD-1 treatment antibody of the PD-L1Positive gastric cancer patient, experiments prove that the serum level of the laminin gamma2 is higher than that of healthy people in the gastric cancer patient and is in positive correlation with a prognosis related factor sPD-L1, the tissue expression of the PD-L1Positive patient is higher, and the serum level of a person without PD-1 antibody treatment response is higher; it is proved that the marker has good progress monitoring value, treatment reaction differences can be effectively distinguished, and the blank of lack of PD-1 antibody curative effect monitoring markers for patients of the type is filled up.

The present invention relates to a method for controlling differentiation of pluripotent stem cells, which method comprises selecting a laminin or a fragment thereof based on binding affinity for the pluripotent stem cells and inducing differentiation of the pluripotent stem cells in the presence of the laminin or a fragment thereof. Here, the binding affinity for cells can be assessed by time-course observation of the survival rate and motility of the cells. According to the present invention, a cell population containing any desired proportion of differentiated cells can be produced from pluripotent stem cells in a simple manner. The cell population obtained by this production method is very useful for cell therapy-based treatment strategies for diseases.

The invention belongs to the technical field of animal reproductive biology and cell engineering, and particularly relates to a fluorescence labeling expression system for visualizing an oocyte nucleus maturation process and application of the fluorescence labeling expression system. The fluorescence labeling expression system comprises an eukaryotic expression vector pVenus-LMNB1; the eukaryotic expression vector pVenus-LMNB1 comprises a nucleotide sequence for coding the fusion protein Venus-LMNB1. According to the invention, a nuclear fiber layer protein stably expressed on a nuclear membrane is selected as a research object, a eukaryotic expression vector pVenus-LMNB1 is constructed by using a molecular cloning technology, an LMNB1 gene containing a green fluorescent label Venus is overexpressed in a porcine oocyte by using a microinjection technology, fluorescent protein labeling of a structural protein on the nuclear membrane is utilized, and the expression vector pVenus-LMNB1 is constructed. The expression positioning condition of the LMNB1 in the maturation process of the porcine oocytes is observed, and a powerful tool is provided for development of in-vitro culture related researches of the porcine oocytes.

The invention relates to the technical field of artificial dermis, in particular to a preparation method and application of artificial dermis based on bionic acellular matrix. The artificial dermis comprises a bionic acellular matrix component A and an auxiliary material component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, mother cell protein and glucan; the component B comprises antibacterial peptide, antibiotics and a high-molecular polymer material; the mass ratio of the component A to the component B is (4-6): (1-4). The preparation method comprises the following steps: respectively preparing procedure mother liquor of the component A and the component B, preparing hydrogel with a double-layer gradient structure through step-by-step crosslinking, and then carrying out freeze drying and sterilization treatment. The artificial dermis disclosed by the invention has good biocompatibility and antibacterial property, can effectively promote wound healing, is suitable for repairing acute and chronic wounds of four limbs, faces and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.

The present invention provides a method for promoting the differentiation of mesenchymal stem cells (MSCs) into oligodendrocyte progenitor cells, which includes primary culturing the isolated MSCs, followed by secondary passage culturing, then treating them with a gene expression vector containing the "key gene for oligodendrocyte progenitor cell differentiation", and further performing differentiation culture using the "oligodendrocyte progenitor cell differentiation medium". Through specific cell differentiation treatment and culture processes, the present invention uses a cell culture matrix treated with recombinant human laminin to culture MSCs and promote their differentiation, so as to obtain oligodendrocyte progenitor cells derived from MSCs in a relatively short time. The present invention further provides a method for efficiently harvesting oligodendrocyte progenitor cells. Specifically, through a rate-limiting shaking method, oligodendrocyte progenitor cells are harvested and allowed to further proliferate, and a relatively large amount of oligodendrocyte progenitor cells with high purity can be harvested in a short time for the production of cell therapy products.

Methods comprise exposing a culture of human pluripotent stem cells adherent on a first substrate comprising a first laminin to a differentiation medium for a first time period of 15 days to 50 days to obtain a first population of adherent cells comprising RPE cells and / or progenitors thereof; at the end of the first time period, dissociating the first population from the first substrate; replating the dissociated first population of cells on a second substrate comprising a second laminin; and culturing the replated first population of cells on the second substrate for a second time period to obtain an expanded and matured second population of cells comprising the RPE cells. The first and second laminins are independently selected from LN-521, LN-511, LN-111 and LN-121, and are an intact protein or protein fragment. Also included are RPE cells and materials and compositions utilizing such RPE cells for various treatments.

The present application relates to the technical field of in vitro diagnosis, disclose a kind of laminin determination kit and preparation method thereof, the reagent kit is composed of reagent 1 and reagent 2, the main component of reagent 1 has ammonium chloride, sodium azide, Brij-35, sodium chloride, PEG6000, EDTA2Na, F (ab') 2 fragment, the main component of reagent 2 has mouse monoclonal antibody coated latex microparticle, Tris-Hcl buffer solution, sucrose, gelatin, Tween-20, NP30, Proclin300, mouse monoclonal antibody coated latex microparticle in the reagent kit has good suspensibility and monodispersity, stably exists in aqueous system, improves the determination intensity and stability of signal. The kit is specific, and high accuracy.

The invention provides a serum-free medium for maintaining dryness of mesenchymal stem cells as well as a preparation method and application of the serum-free medium, and belongs to the technical field of biological medicines. The serum-free culture medium comprises a basic culture medium and an exogenous additive component, the basic culture medium is a DMEM / F12 culture medium, and the exogenous additive components comprise bFGF, EGF, PDGF-BB, recombinant human fibronectin, laminin, insulin, transferrin, sodium selenate, beta-mercaptoethanol and ascorbic acid. The serum-free culture medium provided by the invention is a special culture medium for the mesenchymal stem cells, which is completely free of animal-derived components, is suitable for large-scale amplification of clinical-grade cell treatment products, is relatively low in preparation cost and high in stem differentiation capability, and can remarkably improve the proliferation efficiency of the cultured mesenchymal stem cells.

The present disclosure provides, among other things, a class of antibodies or an antigen binding fragments that bind to calf-1 or calf-2 domain of α7β1 integrin. The anti-α7β1 antibodies of the present disclosure are effective in stabilizing the α7β1 integrin in the extended closed and extended-open conformations, which enhances the binding to laminins.

The present application relates to the technical field of artificial dermis, and particularly relates to a preparation method and application of artificial dermis based on biomimetic acellular matrix. The artificial dermis comprises a biomimetic acellular matrix component A and an auxiliary component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, matricellular protein and dextran; the component B comprises antibacterial peptide, antibiotic and high molecular polymer material; the mass ratio of the component A to the component B is (4-6):(1-4). The preparation method comprises the steps of respectively preparing A and B component process mother liquor, step-by-step crosslinking to prepare a hydrogel with a double-layer gradient structure, and then freeze-drying and sterilization treatment. The artificial dermis has good biocompatibility and antibacterial performance, can effectively promote wound healing, and is suitable for repairing acute and chronic wounds of limbs, facial parts and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

The invention discloses a polyurethane surface bionic coating capable of synergistically resisting blood coagulation and promoting endothelialization and a preparation method, and relates to the technical field of biomedical materials. According to the invention, tannic acid (TA) and polylysine (PLL) are subjected to a Schiff base and Michael addition reaction in a weak alkaline environment to form a covalent cross-linked bionic intermediate layer, and the intermediate layer synergistically loads heparin (Hep) and laminin (Ln) on the surface of polyurethane (PU) to form a multifunctional active coating, so that the polyurethane material with the bionic coating is formed. The surface coating of the polyurethane material significantly reduces platelet adhesion and hemolysis rate, promotes endothelial cell adhesion, proliferation and functional expression, and inhibits excessive proliferation of smooth muscle cells, and the polyurethane material is simple in preparation process, mild in condition and suitable for surface functional modification of blood contact materials such as artificial blood vessels and interventional catheters.

The present invention relates to the field of organoid culture technology, and in particular to a tumor organoid culture hydrogel with clear components and its preparation method and application, wherein the tumor organoid culture hydrogel with clear components includes a gel precursor and laminin 521; the gel precursor is prepared by dissolving sodium alginate and gelatin in PBS; the concentration of laminin 521 is 0.10-0.15mg / ml. The hydrogel components provided by the present invention are clear, and the performance of its cultured tumor organoids is comparable to Matrigel, which overcomes the technical problems that Matrigel has complex components, batch differences, and expensive prices, resulting in the conversion of tumor patient-derived organoid models and limited applications. In addition, the hydrogel components provided by the present invention have a high degree of industrialization, good stability, and are easy to obtain, and standardized and economical production can be achieved, providing support for the construction of tumor organoid models.

Disclosed are compositions and methods for their use that can be used in cosmetic applications. The composition can include an effective amount of a Centella asiatica stem cells to reduce the activity of hyaluronidase in skin, an effective amount of tetradecyl aminobutyroylvalylamino butyric urea trifluoroacetate or Alpinia galanga leaf extract to promote the production of hyaluronic acid in skin, an effective amount of tripeptide-1 to promote the production of fibronectin and laminin in skin, and a dermatologically acceptable vehicle.

The invention belongs to the technical field of medicine, and relates to application of eriodictyol in preparation of a medicine for preventing or treating cholestasis. According to test verification, the eriodictyol can remarkably reduce the content of total bilirubin and total bile acid in serum of a cholestasis mouse constructed by bile duct ligation, and the content of total bile acid in the cholestasis mouse is reduced; the activity of alkaline phosphatase, glutamyl transferase, hyaluronidase and laminin is inhibited, the liver index is reduced, and a new thought is provided for treating cholestasis.

The invention provides a molecular self-assembly integrin patch for regulating and controlling mechanical signals of cells as well as a preparation method and application of the molecular self-assembly integrin patch, and an extracellular matrix (ECM) bionic cell patch is constructed through a molecular self-assembly technology. According to the patch, a laminin-derived integrin binding ligand is extended and self-assembled through an N-terminal aromatic amino acid to form a fibrous nano network, and the patch has controllable nano-scale ligand distribution, network viscoelasticity and stability, and can specifically activate integrin beta1 at the top end of MSC (mesenchymal stem cell), so that a mechanical signal is conducted from a cell membrane to a cell nucleus. The process coordinates cytoskeleton reconstruction, nuclear deformation and chromatin rearrangement, and finally drives the MSC to efficiently differentiate into neuron-like cells under the condition of no exogenous gene or chemical induction, so as to express nerve markers such as TUBB3 and present functional characteristics such as spontaneous calcium transient. The cell patch can be widely applied to nerve regeneration, tissue engineering, disease model construction and intelligent biological material development.

The present invention relates to the technical field of biomedicine, and specifically relates to a modified laminin. By attaching an amino acid linker to the N-terminus of laminin, the interactions between the laminin and culture plates and between the laminin and cells are enhanced, the adherent activity of cells is improved, thereby achieving suspension culture without the need for pre-coating in the cell culture process.

The invention is applied to the technical field of medicine of nano-drugs for treatment, and particularly discloses preparation of a polydopamine nanocomposite and application of the polydopamine nanocomposite in treatment of endometriosis, the polydopamine nanocomposite is polydopamine nanoparticles which are modified by polyethylene glycol and laminin and carry didrogesterone, and the polydopamine nanoparticles are polydopamine nanoparticles which are modified by polyethylene glycol and laminin and carry didrogesterone. The disease is endometriosis. Polydopamine nano-particles which are modified by polyethylene glycol and laminin and carry didrogesterone are constructed and applied to in-vitro and in-vivo experiments related to treatment of endometriosis, and the polydopamine nano-particles have the effects of improving oxidative stress, inhibiting inflammatory microenvironment, promoting ectopic endometrial atrophy, inhibiting inflammation and treating endometriosis. And a good treatment effect is achieved in the aspect of reducing the dosage of the didrogesterone.

The invention relates to the technical field of cosmetics, in particular to polypeptide essence with an anti-alopecia function and a preparation method of the polypeptide essence. The polypeptide composite component is formed by mixing acetyl tetrapeptide-3 and oligopeptide-54 according to the mass ratio of 1: (1-3). The acetyl tetrapeptide-3 can activate fibroblasts, promote synthesis of laminin, III type collagen and VII type collagen, reinforce an epidermis-dermis connecting structure, reduce the hair loss rate and prolong the hair growth period; the oligopeptide-54 can lower hair loss related signal molecules such as DKK-1, stimulate hair follicle activity, promote melanogenesis and improve the problem of premature graying of hair. The combination of the two can synergistically improve the anti-hair loss effect from different action targets, experiments prove that the polypeptide activity in the proportion range is the highest, the excessive addition easily causes component agglomeration and reduces bioavailability, and the expected effect cannot be achieved if the addition is insufficient. The invention has the beneficial effect of high-efficiency hair loss prevention: the polypeptide and the plant extract have a synergistic effect, and the problem of hair loss is solved from multiple dimensions of activating hair follicles, strengthening hair anchoring and improving scalp environment.

Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.

The invention belongs to the technical field of biomedicine, and provides a Lam-pGelMA microsphere aiming at the technical problems existing in the traditional GelMA microsphere, which comprises a GelMA microsphere with a porous structure and a laminin coating with a functionally modified surface. The invention further provides a preparation method of the Lam-pGelMA microspheres. The preparation method comprises the following steps: S1, preparing the GelMA microspheres; s2, preparation of GelMA microspheres of a porous structure; and S3, preparation of Lam-pGelMA microspheres. The Lam-pGelMA microsphere synthesized by the invention has a porous structure, and the surface of the Lam-pGelMA microsphere is functionally modified by laminin, so that a better attachment site can be provided for the growth of NSCs to promote the adhesion growth of the NSCs; and the laminin functional modification can significantly enhance the survival and proliferation activity of the NSCs in the damaged environment.